GSK v. Pfizer: RSV Vaccine Patent Dispute Dismissed With Prejudice After 611 Days
GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC brought a 7-patent infringement action against Pfizer Inc. in the District of Delaware, asserting rights over pre-fusion RSV F antigens and related recombinant RSV antigen technologies. After 611 days of litigation, both parties stipulated to dismiss all claims and counterclaims with prejudice, each bearing its own costs.
GSK’s 7-Patent RSV Antigen Assertion Against Pfizer Ends in Mutual Dismissal
Filed on 2 August 2023 before Judge Maryellen Noreika in the District of Delaware, this action saw GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC assert seven US patents directed to pre-fusion RSV F antigens, RSV F protein compositions, and recombinant RSV antigens against Pfizer Inc. The patents span a range of application dates and collectively cover core structural and formulation innovations in RSV vaccine technology — an area of acute commercial significance given the race to market between GSK’s Arexvy and Pfizer’s Abrysvo RSV vaccines.
The case closed on 4 April 2025 via a stipulated dismissal under Rule 41(a)(1)(A)(ii), with both GSK’s infringement claims and Pfizer’s counterclaims dismissed with prejudice. The with-prejudice designation is legally significant: it operates as a final adjudication on the merits for res judicata purposes, barring GSK from re-asserting these seven patents against Pfizer on the same accused products. Pfizer’s counterclaims — which may have included non-infringement and invalidity defences — are equally extinguished.
The 611-day duration suggests the parties litigated through meaningful procedural stages before reaching resolution, consistent with a negotiated settlement or cross-licensing arrangement rather than a swift nuisance dismissal. The mutual cost-bearing provision is a hallmark of negotiated resolution and suggests neither party extracted a fee concession. The precise commercial terms, if any, underlying this stipulation remain undisclosed in the public record — a common feature of high-value pharma patent settlements.
Filing to Dismissed with Prejudice in 611 days
611 days from filing to dismissal — above the Delaware District Court median for patent cases
Dismissed with prejudice: what the stipulated termination means for both parties
Rule 41(a)(1)(A)(ii) stipulated dismissal with prejudice explained
A Rule 41(a)(1)(A)(ii) dismissal requires agreement of all parties and carries the legal weight of a final judgment when filed with prejudice. Unlike a voluntary unilateral dismissal, this is a bilateral stipulation — both GSK’s claims and Pfizer’s counterclaims are extinguished. Courts treat such dismissals as adjudications on the merits, activating res judicata and preventing re-litigation of the same patent-product combinations between these parties.
Final adjudication on the meritsGSK’s seven RSV patents survive — but enforcement against Pfizer is now barred
GSK retains ownership of all seven asserted patents; the dismissal does not invalidate them. However, the with-prejudice disposition means GSK cannot resurrect these specific infringement claims against Pfizer on the same accused RSV products. The patents remain fully enforceable against third parties. If a confidential licensing arrangement underlies the resolution, GSK may have secured ongoing royalty flows — but the public record is silent on any such terms.
Patents intact; Pfizer enforcement barredPfizer’s counterclaims dismissed — invalidity challenge to GSK patents unresolved
Pfizer’s counterclaims, which typically in patent infringement actions include non-infringement declarations and invalidity challenges, are dismissed with prejudice alongside GSK’s claims. This means Pfizer cannot pursue a court-adjudicated invalidity ruling against these seven patents through this action. Whether Pfizer retains the ability to challenge patent validity via IPR proceedings at the USPTO is a separate question not resolved by this dismissal.
Counterclaims extinguishedRSV vaccine IP landscape: a bilateral standoff resolved outside public record
The mutual dismissal with prejudice and equal cost-bearing provision is consistent with a cross-licence or co-existence agreement between two of the RSV vaccine market’s dominant players. For the broader RSV vaccine sector, these seven patents remain valid and enforceable threats against any third-party entrant. Emerging RSV vaccine developers and biosimilar manufacturers should treat GSK’s pre-fusion F antigen portfolio as an active freedom-to-operate risk.
Third-party FTO risk remains elevatedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Glaxosmithkline Biologicals, SA | Company | Biopharmaceutical vaccine developer — holder of US11655284B2 and 6 RSV F antigen patentsSearch in Eureka ↗ |
| Co-Plaintiff | Glaxosmithkline, LLC | Company | Search in Eureka ↗ |
| Defendant | Pfizer, Inc. | Company | Pfizer Inc. — global pharmaceutical company and RSV vaccine competitor (Abrysvo)Search in Eureka ↗ |
| Plaintiff counsel | Christopher R. Noyes | Attorney | Counsel for Glaxosmithkline Biologicals, SASearch in Eureka ↗ |
| Plaintiff counsel | Frederick L. Cottrell , III | Attorney | Counsel for Glaxosmithkline Biologicals, SASearch in Eureka ↗ |
| Plaintiff counsel | Kelly E. Farnan | Attorney | Counsel for Glaxosmithkline Biologicals, SASearch in Eureka ↗ |
| Plaintiff counsel | Lisa J. Pirozzolo | Attorney | Counsel for Glaxosmithkline Biologicals, SASearch in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Glaxosmithkline Biologicals, SASearch in Eureka ↗ |
| Plaintiff counsel | Robert J. Gunther , Jr. | Attorney | Counsel for Glaxosmithkline Biologicals, SASearch in Eureka ↗ |
| Plaintiff counsel | Sara M. Metzler | Attorney | Counsel for Glaxosmithkline Biologicals, SASearch in Eureka ↗ |
| Plaintiff counsel | Stephanie Lin | Attorney | Counsel for Glaxosmithkline Biologicals, SASearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Glaxosmithkline Biologicals, SASearch in Eureka ↗ |
| Plaintiff law firm | Richards, Layton & Finger, PA | Law Firm | Representing Glaxosmithkline Biologicals, SASearch in Eureka ↗ |
| Defendant counsel | Amit H. Thakore | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Defendant counsel | Dimitrios T. Drivas | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Defendant counsel | Elizabeth Chang | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Defendant counsel | John P. Scheibeler | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Defendant counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Defendant law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Pfizer, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Maryellen Noreika | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation invokes Rule 41(a)(1)(A)(ii), requiring written consent from all parties — a procedurally higher bar than a unilateral plaintiff dismissal. The explicit with-prejudice designation for both GSK’s claims and Pfizer’s counterclaims is notable: it is not the default outcome under Rule 41(a)(1), which ordinarily yields a without-prejudice dismissal. The parties’ affirmative election of with-prejudice treatment, combined with mutual cost-bearing, suggests a negotiated resolution in which both sides accepted finality in exchange for undisclosed commercial terms.
US11655284B2 — Pre-Fusion RSV F Antigen Compositions
US11655284B2, the lead patent in this action, protects pre-fusion stabilised RSV F antigens — a structurally distinct conformation of the RSV fusion protein that is significantly more immunogenic than the post-fusion form. Pre-fusion F antigen stabilisation is the foundational innovation underlying both GSK’s Arexvy and Pfizer’s Abrysvo RSV vaccines. The six co-asserted patents (US8563002B2, US11827694B2, US12139512B2, US11629181B2, US11820812B2, US11261239B2) extend protection across composition, formulation, and method-of-making dimensions of RSV F protein technology, creating a layered portfolio spanning multiple application dates.
The strategic significance of this portfolio is substantial: RSV vaccines represent a multi-billion dollar annual market following FDA approvals in 2023, and pre-fusion F antigen technology is the central enabling platform for the leading approved products. GSK’s assertion of seven patents simultaneously suggests a broad-based enforcement posture designed to establish licensing leverage rather than simply halt a single product feature. For any company developing RSV vaccines, mRNA-based RSV immunogens, or RSV F protein-based therapeutics, this portfolio represents the primary IP barrier to market entry.
Should your RSV vaccine programme run an FTO against US11655284B2?
Any R&D team working on RSV F protein-based vaccines, recombinant RSV antigen platforms, or stabilised fusion protein immunogens should treat GSK’s seven-patent portfolio as a priority FTO target. The patents collectively cover compositions, recombinant constructs, and manufacturing methods — meaning a product may implicate multiple claims across several patents simultaneously. The dismissal of this action does not reduce third-party risk; it confirms only that GSK and Pfizer have resolved their bilateral dispute.
PatSnap Eureka’s FTO Search Agent can map your antigen design against the claim scope of all seven asserted patents, identify relevant prior art that was or was not cited during prosecution, and flag continuation applications that may extend the portfolio’s reach. Given that RSV vaccine patent families typically involve multiple continuations and divisionals, automated claim-change monitoring is strongly advisable for programmes at IND stage or later.
Run a freedom-to-operate analysis on US11655284B2 to assess your product’s exposure
Run FTO in Eureka →Similar RSV Vaccine and Biologics Patent Cases in Delaware Federal Court
Explore related patent infringement actions involving RSV antigens, pre-fusion F protein technology, and vaccine biologics litigated in the District of Delaware.
What this case signals for the RSV vaccine IP landscape
A mutual with-prejudice dismissal between RSK market leaders typically signals negotiated resolution — with significant implications for future entrants.
Seven RSV F antigen patents remain enforceable against all third parties
The dismissal leaves GSK’s seven-patent RSV portfolio fully intact and actionable. Any company developing RSV vaccines or RSV F protein-based therapeutics — outside the scope of this particular bilateral resolution — faces a live infringement risk from this portfolio. Early FTO analysis against US11655284B2 and its six co-asserted patents is essential before entering this space.
Mutual cost-bearing signals negotiated resolution, not litigation defeat
Equal cost allocation in a with-prejudice stipulation is a strong signal that commercial terms — potentially a licence, cross-licence, or market co-existence agreement — were reached privately. This pattern is common in pharma patent disputes where both parties have significant revenue at stake and public invalidation of key patents would be commercially damaging to the patent holder.
Glaxosmithkline v Pfizer — key questions answered
A dismissal with prejudice under Rule 41(a)(1)(A)(ii) is treated as a final adjudication on the merits. GSK cannot re-file these infringement claims against Pfizer based on the same seven patents and the same accused RSV products. Pfizer’s counterclaims — including any invalidity challenges — are also permanently extinguished under this stipulation.
GSK asserted seven US patents: US11655284B2, US8563002B2, US11827694B2, US12139512B2, US11629181B2, US11820812B2, and US11261239B2. These patents collectively cover pre-fusion RSV F antigens, RSV F protein compositions, methods of making recombinant RSV antigens, and related immunogenic constructs central to RSV vaccine technology.
No. A stipulated dismissal with prejudice does not adjudicate patent validity. All seven patents remain in force and are enforceable against third parties. The dismissal resolves only the bilateral dispute between GSK and Pfizer — it does not constitute a finding of invalidity, non-infringement, or unenforceability by the court.
The district court dismissal does not directly preclude USPTO inter partes review petitions. However, Pfizer’s statutory one-year IPR bar under 35 U.S.C. § 315(b) — triggered by service of the complaint in August 2023 — has likely elapsed for most or all of the asserted patents. Third parties unrelated to this litigation remain free to petition for IPR against GSK’s RSV patent portfolio.
GSK was represented by Morris, Nichols, Arsht & Tunnell LLP and Richards, Layton & Finger PA, with lead counsel including Christopher R. Noyes, Lisa J. Pirozzolo, and Frederick L. Cottrell III. Pfizer was also represented by Morris, Nichols, Arsht & Tunnell LLP, with counsel including Dimitrios T. Drivas and Amit H. Thakore. The case was presided over by Judge Maryellen Noreika.
PatSnap Eureka searches patents and litigation data to answer instantly.